Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Open-Angle Glaucoma Pipeline Report 2016: Therapeutics Review of 22 Companies & 38 Drug Molecules - Research and Markets

Research and Markets
Posted on: 10 Oct 16

Research and Markets has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2016" report to their offering.

Open-Angle Glaucoma pipeline therapeutics constitutes close to 38 molecules. Out of which approximately 36 molecules are developed by Companies and remaining by the Universities/Institutes.

Open-Angle Glaucoma - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Open-Angle Glaucoma Open-angle glaucoma also called wide-angle glaucoma, this is the most common type of glaucoma. The structures of the eye appear normal, but fluid in the eye does not flow properly through the drain of the eye, called the trabecular meshwork. Signs and symptoms include gradual loss of peripheral vision, usually in both eyes and tunnel vision in the advanced stages. Risk factors include age, family history of glaucoma, long-term corticosteroid use and elevated internal eye pressure (intraocular pressure).

The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 9, 17, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Open-Angle Glaucoma Overview
  3. Therapeutics Development
  4. Pipeline Products for Open-Angle Glaucoma - Overview
  5. Pipeline Products for Open-Angle Glaucoma - Comparative Analysis
  6. Open-Angle Glaucoma - Therapeutics under Development by Companies
  7. Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes
  8. Open-Angle Glaucoma Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Open-Angle Glaucoma - Products under Development by Companies
  13. Open-Angle Glaucoma - Products under Investigation by Universities/Institutes
  14. Open-Angle Glaucoma - Companies Involved in Therapeutics Development
  • Aerie Pharmaceuticals, Inc.
  • Allergan Plc
  • Amakem NV
  • Bausch & Lomb Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Glaukos Corporation
  • Inotek Pharmaceuticals Corporation
  • Isarna Therapeutics GmbH
  • Kowa Company, Ltd.
  • Laboratoires Thea S.A.
  • Laboratorios Sophia S.A. de C.V.
  • Lee's Pharmaceutical Holdings Limited
  • Lexicon Pharmaceuticals, Inc.
  • Ocular Therapeutix, Inc.
  • Otsuka Holdings Co., Ltd.
  • Oxford BioMedica Plc
  • Sanofi
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co., Ltd.
  • Sun Pharma Advanced Research Company Ltd.
  • Sylentis S.A.U.
  • ViSci Ltd.

For more information about this report visit

View source version on

Business Wire

Last updated on: 10/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.